Setara, a new biotech formed after Jazz Pharmaceuticals acquired Actio Biosciences, raised a $90 million Series A to pursue rare disease genetics at scale. The company is carrying forward a pipeline that Jazz inherited from Actio, with Setara newly positioned as the owner of the programs under the Actio strategy. Setara’s lead program, STAR-0871 (TRPV4 inhibitor), targets Charcot-Marie-Tooth disease type 2C, an inherited neuromuscular disorder caused by gain-of-function TRPV4 mutations. The company said the therapy aims to block an overactive ion channel at the genetic root rather than managing symptoms, with an estimated U.S. patient population around 2,500. Beyond the rare disease lead, Setara is attempting to extend TRPV4 biology into overactive bladder through what it describes as a “one to many” approach. Jazz Pharmaceuticals joined the financing as a new shareholder after the Actio acquisition, and Setara said it retained Actio’s existing investor network for continuity.